Ropes & Gray Advised Genzyme Corporation on “Deal of Distinction” Award-Winning Deal

In The News
October 1, 2010
Ropes & Gray advised Genzyme Corporation on the $2.9 billion deal with Bayer Schering Pharma AG that received a “Deal of Distinction” award from the Licensing Executives Society. The 2009 deal bolstered Genzyme’s oncology portfolio by giving the company rights to marketed cancer drugs and control of a program in multiple sclerosis.
The “Deal of Distinction” award recognizes the most distinctive deal in the life sciences sector in 2009. The Licensing Executives Society is a professional society with nearly 5,000 members engaged in the development, use, transfer, marketing, and management of intellectual property.
The cross-practice Ropes & Gray deal team was led by Boston-based corporate partners Chris Comeau (Securities & Public Companies), David McIntosh (IP Transactions), Walter McCabe (Real Estate) and Paul Kinsella (Securities & Public Companies).